|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1. Quality assessment of evidence per outcome using the Grading of Recommendations Assessment, Development, and Evaluation approach** | | | | | | | | | | | |
| **Treatment outcome** | **Studies**  **(*n*)** | **Study**  **design** | **Study quality** | **Risk**  **of bias** | **Consistency** | **Directness** | **Other considerations** | **Patients (*n*)**  **event/total (%)** | | **Quality** | **Importance** |
| Cyclosporine | 11 | Observational | Predominantly  retrospective data  small sample sizes | High† | Inconsistencies‡ | Direct | None | Remission  Response  Treatment  failure | 35/58 (60)  13/58 (22)  6/58 (10) | +OOO  Very low | Critical |
| Tacrolimus | 11 | Observational | Predominantly  retrospective data  Predominantly  small sample sizes | High† | Inconsistencies‡ | Direct | None | Remission  Response  Treatment failure | 129/211 (61)  29/211 (14)  27/211 (13) | +OOO  Very low | Critical |
| CNI in  first-line  insufficient response | 18 | Observational | Predominantly  retrospective data  Predominantly  small sample sizes | High† | Inconsistencies‡ | Direct | None | Remission  Response  Treatment failure | 104/195 (53)  33/195 (17)  13/195 (7) | +OOO  Very low | Critical |
| CNI in  first-line intolerance | 10 | Observational | Predominantly  retrospective data  Predominantly  small sample sizes | High† | Inconsistencies‡ | Direct | None | Remission  Response  Treatment failure | 40/56 (71)  1/56 (2)  2/56 (4) | +OOO  Very low | Critical |
| CNI as  second-line treatment | 20 | Observational | Predominantly  retrospective data  Predominantly  small sample sizes | High† | Inconsistencies‡ | Direct | None | Remission  Response  Treatment failure | 105/196 (54)  16/196 (8)  18/196 (9) | +OOO  Very low | Important |
| CNI as  third-line treatment | 10 | Observational | Only  retrospective data  Predominantly  small sample sizes | High† | Inconsistencies‡ | Direct | None | Remission  Response  Treatment failure | 16/60 (27)  10/60 (17)  2/60 (3) | +OOO  Very low | Important |
| † Only case series and case reports. High risk of publication and selection bias; ‡ Heterogeneity in outcome measures and missing data. | | | | | | | | | | | |